Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD)

Review began 12/21/2021
Review ended 12/27/2021
Published 12/28/2021

© Copyright 2021

Parameswaran et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Madhangi Parameswaran¹, Hamzah A. Hasan², Jafor Sadeque³, Sharan Jhaveri⁴, Chaithanya Avanthika⁵, Abimbola E. Arisoyin⁶, Maulik B. Dhanani⁷, Swaroopa M. Rath⁸

1. Radiology, Massachusetts General Hospital, Boston, USA 2. School of Medicine, Hashemite University, Zarqa, JOR 3. Internal Medicine, Al Mostaqbal Hospital, Jeddah, SAU 4. Internal Medicine, Smt. Nathiba Hargovandas Lakhmichand Municipal Medical College, Ahmedabad, IND 5. Medicine and Surgery, Karnataka Institute of Medical Sciences, Hubli, IND 6. Internal Medicine, College of Medicine, University of Lagos, Lagos, NGA 7. Internal Medicine, Southwestern University School of Medicine, Cebu City, PHL 8. Medicine, Srirama Chandra Bhanja Medical College and Hospital, Cuttack, IND

Corresponding author: Sharan Jhaveri, sharan98jhaveri@gmail.com

Abstract

Non-alcoholic fatty liver disease (NAFLD) refers to a spectrum of diseases involving the deposition of fat in the hepatocytes of people with little to no alcohol consumption. NAFLD is associated with hypertension, diabetes, obesity, etc. As their prevalence increases, the propensity and severity of NAFLD might increase. As per the recently developed multi-hit hypothesis, factors like oxidative stress, genetic predisposition, lipotoxicity, and insulin resistance have been found to play a key role in the development of NAFLD and its associated complications. This article focuses on NAFLD, its pathophysiology, risk factors, and the various genetic and epigenetic factors involved in its development along with possible treatment modalities.

We conducted an all-language literature search on Medline, Cochrane, Embase, and Google Scholar until October 2021. The following search strings and Medical Subject Heading (MeSH) terms were used: "NAFLD," "NASH," "Fibrosis," and "Insulin Resistance." We explored the literature on NAFLD for its epidemiology, pathophysiology, the role of various genes, and how they influence the disease and associated complications about the disease and its hepatic and extrahepatic complications. With its rapidly increasing prevalence rates across the world and serious complications like NASH and hepatocellular carcinoma, NAFLD is becoming a major public health issue and more research is needed to formulate better screening tools and treatment protocols.

Categories: Internal Medicine, Gastroenterology

Keywords: treatment choices, mitochondrial senescence, demographics, long-term prognosis, disease progression, human genetics and epigenetics, nonalcoholic fatty liver disease (naflD)

Introduction And Background

Non-alcoholic fatty liver disease (NAFLD) refers to a spectrum of diseases caused by deposition of fats in more than 5% of hepatocytes, primarily in the form of triglycerides in the absence of alcohol consumption (over 21 drinks/week for men and 14 drinks/week for women), use of medications causing hepatic steatosis, or hereditary and autoimmune causes [1]. The histological presentation can range from the bland accumulation of triglycerides within the hepatocytes (fatty liver) to non-alcoholic steatohepatitis (NASH). Fatty liver is a benign non-progressive form of the disease, whereas NASH is associated with inflammation, hepatocyte ballooning, and deposition of collagen fibers that can eventually progress to cirrhosis and liver cancer [2].

After Mayo Clinic first described the occurrence of NAFLD in 1980, the pathogenesis has been widely studied, although the exact mechanism is still unknown [3,4]. According to previous research that describes the "two-hit hypothesis," the first strike is represented by increased hepatic triglyceride content and resistance to insulin. This vulnerable liver is then subjected to a second hit, which comprises inflammatory cytokines, adipokines, mitochondrial dysfunction, and oxidative stress [5]. At present, the "multiple hit model" is the commonly accepted idea that involves the association with metabolic dysfunction and interactions of complex environmental and genetic influences. NAFLD is now considered the hepatic manifestation of metabolic syndrome and is closely associated with high triglyceride level content, low high-density lipoprotein (HDL), hypertension, and morbid obesity [6].

As it requires histological diagnosis, the gold standard for diagnosis of NAFLD is liver biopsy. But specific non-invasive modalities are acceptable, including hepatic ultrasonography (USG), abdominal computed tomography (CT) scan, and magnetic resonance imaging (MRI) [7]. Serum biomarkers such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have been used for screening [8]. The prevalence of NAFLD in the general population in various nations is estimated to range from 3% to more than 24% using blood markers [8]. NASH affects around 6-8% of individuals in the United States (about 25% of those with NAFLD) [9]. If these studies are assumed to represent the wider population, it would imply

How to cite this article

Parameswaran M, Hasan H A, Sadeque J, et al. (December 28, 2021) Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD). Cureus 13(12): e20776. DOI 10.7759/cureus.20776

cirrhosis in 1.5-2% of the US population owing to NAFLD [9].

While the progression to cirrhosis is rare, subsequent chances of development to primary liver cancer can be as high as 3%. The incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma associated with NAFLD is gradually increasing [10]. Documentation of progressive hepatic fibrosis is used as an important surrogate marker for advanced liver disease. In recent studies, the annual fibrosis progression rate was found to be 0.09 times (95% CI: 0.06-0.12) in patients with baseline NAFLD [11]. In the United States, NASH is the second most common cause of liver disease among transplant recipients [12]. With the rise in the incidence of obesity, hypercaloric diet, and sedentary lifestyle, NAFLD has become the dominant form of chronic liver disease among the pediatric and adolescent age group, with cases detected as young as three years [13,14]. Over the last decade, many treatments have been developed and tested, but no effective treatment is currently available [15]. Thus, it becomes crucial to identify the demography at the highest risk and the elements that influence the advancement of NAFLD.

Review

Pathogenesis and molecular mechanisms of NAFLD

Typically, two pathologically different conditions are identified: non-alcoholic fatty liver (NAFL) and NASH. On the one hand, NAFL is characterized by simple liver steatosis; on the other hand, NASH is identified by the presence of macrovesicular fat accumulation, hepatic ballooning, and lobular inflammation with or without any fibrosis [16-18].

NAFLD is a multifactorial disease, and its pathogenesis and progression are not fully understood. It is a complex disease that interacts with other organs in the body, for instance, on the intestine-liver-adipose tissue axis for its development. Multiple pathways have been proposed over the past years on how NAFLD progresses [19]. Although the most famous theory to explain NAFLD is the “two-hit hypothesis,” a more accurate explanation of NAFLD pathogenesis explained that several molecular and metabolic changes occur together in its development and progression. This “multiple hit” hypothesis considers multiple insults acting in concert to cause NAFLD [19,20].

Lipotoxicity and NAFLD

Hepatic lipotoxicity happens when the liver's capacity to use, reserve, and export free fatty acids (FFAs) as triglycerides (TGs) is saturated by a massive FFA influx from the periphery, mainly the adipose tissue or by increased hepatic de novo lipogenesis [21-23].

FFAs are exported from the liver as very-low-density lipoprotein (VLDL) or stored in hepatic lipid droplets after being metabolized via mitochondrial β -oxidation or re-esterification into TGs inside the hepatocytes. Lipid droplets inside the hepatocytes undergo lipolysis and release fatty acids into the hepatocyte FFA pool [24-26]. Lipotoxic species formed from excess FFA inside liver cells cause endoplasmic reticulum inflammation, oxidative stress, and activation of inflammatory mediators [27-29].

Insulin Resistance and NAFLD

Insulin resistance plays a vital role in the pathogenesis of NAFLD [30]. The role of insulin in our body is to stimulate glucose utilization and increase lipid accumulation in insulin-sensitive organs such as skeletal muscle, adipose tissue, and liver. Insulin resistance leads to increased lipolysis in dysfunctional adipose tissue and reduced glucose uptake in skeletal muscle [27,28]. As a result, there is an increased FFA in the bloodstream and the liver as well. Higher hepatic uptake of FFA leads to the accumulation of TGs in the liver and the release of VLDL via fatty acid esterification.

In contrast, glucose uptake contributes to a lesser extent via de novo lipogenesis, leading to steatosis (NAFL) and dyslipidemia [26]. Studies have shown metabolic cross-talk between liver and adipose tissue [30]. Some peptides released by adipose tissue, such as adiponectin and interleukin 6 (IL6), have both proinflammatory and protective effects on the liver [31,32]. The enzyme dipeptidyl peptidase 4 (DPP-4) can promote insulin resistance. This enzyme, secreted by hepatocytes, has been seen to work on plasma factor Xa to stimulate macrophages within the visceral tissue of mice. This mechanism is known to promote insulin resistance, emphasizing the important cross-talk between the liver and other tissues underlying metabolic dysregulation in NAFLD [33].

Oxidative Stress

Oxidative stress plays an important role in the pathogenesis of NAFLD [34,35]. Oxidative stress means the imbalance between the production of reactive oxygen species (ROS) and the scavenging capacity of the antioxidant system [36]. Mitochondria are the most important source of ROS in NAFLD, mainly due to increased fatty acid oxidation (FAO) [37]. At high concentrations, ROS cause oxidative modifications to cellular macromolecules (DNA, lipids, proteins, etc.) and cause accumulation of damaged macromolecules,

initiating liver injury [35].

ROS can initiate lipid peroxidation by targeting polyunsaturated fatty acids, resulting in highly reactive aldehyde products such as 4-hydroxy-2-nonenal (4-HNE) and malondialdehyde (MDA). These reactive compounds have longer half-lives than free radicals and can diffuse into the extracellular space to boost tissue damage. Multiple studies have reported that both MDA and 4-HNE are increased in experimental animal models of NASH and in NASH patients compared to patients with NAFL [35-38].

Cytochrome P450, lipoxygenase, and cyclooxygenase, well-characterized pro-oxidant systems, combined with free-radical products, have been involved in the early stages of NAFLD [39,40]. On the contrary, a reduction in the activity of antioxidant enzymes such as catalase, glutathione peroxidase, glutathione S-transferase, superoxide dismutase, as well as ROS scavengers (ascorbic acid, glutathione, α -tocopherol, ubiquinone, thioredoxin, and bilirubin) is a characteristic of livers from NASH patients [38,39,41].

Immune Cells Involved in NAFLD

Multiple immune cells are involved in developing NAFLD, such as activated Kupffer cells, the liver's resident macrophages, in combination with the recruitment of proinflammatory, monocyte-derived macrophages and neutrophil leukocytes from circulation [42,43]. With the substantial accumulation of macrophages, their polarization appears "proinflammatory" at the expense of anti-inflammatory and repair macrophages, likely because of the high abundance of proinflammatory cytokines such as interferon- γ , tumor necrosis factor (TNF), and lipopolysaccharide in NASH [44].

Epidemiology and risk factors of NAFLD

NAFLD has been increasing remarkably worldwide in recent years. It is estimated that the current prevalence of NAFLD exceeds 24% of the population globally [11], which implicitly indicates the increase in liver-related morbidity and mortality in the next few years [45,46]. The main cause for concern of NAFLD (particularly NASH) is that it is one of the commonest causes of hepatocellular cancer (HCC) and is expected to supersede viral hepatitis as the most common etiology for HCC in the United States due to the rapidly growing epidemic of metabolic syndrome [47,48]. NASH is also considered an increasing cause of liver transplantation in the US, UK, and also in developing countries [49].

Although the NAFLD disease spectrum ends with cirrhosis, hepatocellular carcinoma (HCC), cardiac events, and chronic kidney disease (CKD) are the major causes of death among NAFLD patients [50]. In addition, one study suggested a relationship between multiple NAFLD comorbidities and the poor prognosis of coronavirus disease 2019 (COVID-19) in NAFLD-infected individuals [51]. Due to its wide-ranging effects on multiple body systems, it is important to initiate a non-invasive screening method to detect NAFLD early.

Tables 1, 2 show the estimated prevalence of NAFLD globally according to regions and race, respectively. The highest prevalence is in the Middle East and South America (around 30%) and the lowest in Africa (13%) [11]. The effect of gender on NAFLD progression is not clear [52], but recent studies showed that males are more likely to develop NASH [53,54].

Region	Estimated prevalence	Notes
North America	27%-34% [55]	N/A
South America	31% [11]	Brazil reported the highest NAFLD prevalence and Peru the lowest[56]
Europe	25% [11]	Varies by countries with a reported low prevalence rate of 8% in Romania to a reportedly high prevalence of 45% in Greece [57]
Asia	15%-20% [58]	These rates are higher in urban areas than those reported from rural areas indicating the highly increasing change of Asian lifestyle in urban areas [11]
Africa	13% [11]	Could be low due to a poor reporting system [59]
Middle East	32% [11]	N/A

TABLE 1: Prevalence of NAFLD in different regions.

NAFLD, non-alcoholic fatty liver disease.

Race	Estimated prevalence	Notes
Hispanic Americans	45% [60]	Highest prevalence
African Americans	24% [60]	Lowest prevalence
European American	33% [60]	N/A
Asians American	18% [61]	N/A
Hispanics Mexicans	33%	Higher prevalence of NAFLD than Hispanics of Dominican origin (16%), and Hispanics of Puerto Rican origin (18%)

TABLE 2: Prevalence of NAFLD in different ethnicities.

NAFLD, non-alcoholic fatty liver disease.

Risk Factors of NAFLD

There are many established risk factors for NAFLD development and progression. A strong association has been found between diabetes mellitus type 2 (DM2) and NAFLD as a large proportion of DM2 patients have NAFLD. It is thought that insulin resistance plays a critical role at the cellular level in the pathogenesis of both conditions [62]. Other risk factors are somehow related to DM2, as obese people, who are at higher risk of DM2 [63], have a higher prevalence of NAFLD.

A study showed that >95% of patients with morbid obesity undergoing bariatric surgery would develop NAFLD in their life [64]. Because of this strong relationship between obesity and NAFLD, waist circumference has been suggested as a simple indicator for the risk of NAFLD development [65]. In addition, weight reduction strategies are emphasized as a preventive method of NAFLD development and progression [66]. A sedentary lifestyle and poor eating habits (high fructose (sugar) drinks and fatty food) are shared risk factors for the development of NAFLD and DM2 [67,68].

Studies among the Asian population showed that sarcopenia, the loss of skeletal muscle mass, has also been associated with the increasing severity of NAFLD [69]. This association needs further validation in the western world [69,70]. Women with subclinical metabolic disturbances are at higher risk of developing NAFLD after menopause, highlighting the protective role of estrogen in women before menopause [71].

Some studies stated that NAFLD could pass through generations, for instance, the metabolic phenotype of obese pregnant women could be transmitted to offspring, making them more susceptible to obesity and NAFLD [53,54]. Regarding gender, it is widely accepted that the male sex has an increased incidence of NAFLD. However, the role of sex in NAFLD progression remains inconclusive. Some studies report sex as an independent predictive factor of NAFLD severity, while others suggest exposure to estrogen to be a better metric [72]. The effect of sex hormones needs to be investigated further to elucidate their role.

Factors for NASH Development

Most studies are in agreement with shared factors that lead to NASH development. Factors associated with NASH development are body mass index (BMI) > 27 and lower hip-to-waist ratios. In addition, specific laboratory investigations were statistically significant, as elevated levels of ALT, AST, and serum sphingolipids (particularly ceramide) with low levels of HDL cholesterol were all associated with NASH development and progression [73-77]. Recently, a study by Tasneem et al. came up with a scoring system called the GULAB (based on gender, US liver findings, lipid (fasting) levels, ALT level, and BMI) score. It consists of several non-invasive parameters with a cutoff point of 5 associated with NASH development [74]. Another study by Seko et al. considered persistent elevation of ALT despite treatment as a valid indicator of NASH histological progression. It recommended strict control of serum ALT to prevent NAFLD progression [77].

Factors Inducing Advanced Fibrosis in NAFLD Patients

NASH patients with advanced fibrosis have a higher risk of developing liver cirrhosis that ends with liver cell failure [78]. Established factors associated with advanced fibrosis in NAFLD patients were male gender, age > 40 years, Caucasian ethnicity, DM2, hypertension, and a lower hip-to-waist ratio. Also, AST/ALT ratio > 1 and raised gamma-glutamyl transferase (GGT) were also noted in advanced fibrotic liver patients [73,74,79]. Thus patients with NASH are advised to check for cirrhosis in case of the presence of these parameters. Patients with NASH are at high risk of developing fibrosis, while patients with NAFL were a point of conflict, as many studies considered their condition as benign that would not develop liver fibrosis [80,81]. On the other hand, more recent studies found that NAFL patients may end up with liver fibrosis, but the progression is slower than NASH patients [79,82].

Genetic and epigenetic factors

Family studies and twin studies estimate the heritability of NAFLD between 20% and 70%, suggesting a vital genetic component for its development and progression [83]. The evolution of genome-wide association studies (GWAS) and candidate gene studies have helped identify numerous genes involved in lipid handling, insulin signaling, and even innate immunity. A select number of genes are summarized in the table below (Table 3). The most robust evidence across multiple ethnicities is for the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene, substituting isoleucine with methionine [84,85]. It produces a dysfunctional lipase enzyme that interferes with triglyceride metabolism and increases the probability of hepatic steatosis [86]. In addition, the PNPLA3 variant is also associated with the development of fibrosis and a five-fold increase in the risk of HCC [87]. The membrane-bound O-acyl transferase 7 (MBOAT7) gene involved in phospholipid metabolism has also been identified to increase the risk of NAFLD development and progression, particularly in the European population [88-90]. This gene has also been associated with a two times increase in risk for HCC [91]. The transmembrane 6 superfamily member 2 (TM6SF2) gene has also been implicated in NAFLD incidence and hepatic fibrosis development in Europeans [92,93]. This gene is involved in liver secretion of very-low-density lipoprotein; a loss-of-function mutation increases hepatic steatosis while protecting cardiovascular disease (CVD) risk [94]. However, this association has not been replicated in other ethnicities [95]. Table 3 is a brief summary of the various genes associated with NAFLD development and progression.

Gene	Variant	Biochemical effects	Effect on NAFLD
PNPLA3	rs738409	Triglyceride metabolism	Increases incidence, progression, and HCC risk [84-87]
MBOAT7	rs641738	Phospholipid metabolism	Increases incidence, progression, and HCC risk [88-91]
TM6SF2	rs58542926	VLDL secretion	Increases incidence and progression [92-93]
Glucokinase regulator (GCKR)	rs780094	De novo lipogenesis	Increases incidence and progression [96]
17β-hydroxysteroid dehydrogenase 13 (HSD17B13)	rs72613567	Possibly lipid-related inflammation	Decreases progression [97]
Interleukin - 28B (IL28B)	rs12979860	Innate immunity	Decreases fibrosis [98]
Superoxide dismutase 2 (SOD2)	rs4880	Oxidative stress protection	Increases fibrosis [99]

TABLE 3: Genes associated with NAFLD progression with a short description of their biochemical processes.

NAFLD, non-alcoholic fatty liver disease; HCC, hepatocellular carcinoma; VLDL, very-low-density lipoprotein; PNPLA3, patatin-like phospholipase domain-containing protein 3; MBOAT7, membrane-bound O-acyl transferase 7; TM6SF2, transmembrane 6 superfamily member 2.

Genetic risk scores are proposed to stratify the severity of NAFLD based on the identified variants [100]. A recent study has demonstrated a better prediction of HCC risk when using genetic risk scores combining the PNPLA3, TM6SF2, glucokinase regulator (GCKR), MBOAT7, and 17β-hydroxysteroid dehydrogenase 13 (HSD17B13) variants [101].

Recent GWAS studies have identified new candidate genes, which may contribute to the genetic risk of NAFLD. For example, associations between a variant in the sorting and assembly machinery component 50 (SAMD50) and NAFLD incidence are reported in Asian and Mexican populations [102]. In addition, variants in glycerol-3-phosphate acyltransferase, mitochondrial (GPAM) and apolipoprotein E (APOE) genes are also identified to be associated with liver fat in the European population [103]. Validation studies need to be performed to understand the effects of the identified variants, which may add to the development of more robust genetic risk scores.

Epigenetics

Epigenetics is described as genetic modification without changes to deoxyribonucleic acid (DNA) sequences to cause a phenotypic change. Its role in the progression of NAFLD via DNA methylation, histone modification, and changes in microRNA (miRNA) expression is gathering increasing attention [94]. DNA methylation refers to the transfer of a methyl group to form 5-methylcytosine at cytosine-guanine dinucleotide (CpG) islands to reduce gene transcription [104].

Changes in methylation of CpG islands in the PNPLA3 gene and fibrogenic genes such as platelet-derived growth factor (PDGF) and transforming growth factor beta (TGFβ) have been associated with the progression of fibrosis [105]. A recent study has demonstrated a change in expression of 288 genes in samples with fibrosis along with a change in cell composition driven by DNA methylation [106]. This highlights the potential of DNA methylation to be the driving factor of fibrosis in NAFLD. Methylation of mitochondrial genes such as NADH dehydrogenase 6 (MT-ND6) in the liver has also been associated with more severe forms of NAFLD [107].

Recent studies have shown a dietary component in DNA methylation as methylation is driven by folate-dependent methyltransferases [104]. It has also been demonstrated that a high-fat diet leads to hypermethylation of peroxisome proliferator-activated receptor gamma (PPARγ), which is linked to triglyceride accumulation [108]. Hence, dietary interventions could act as a potential therapy for the reversal of NASH.

Changes in acetylation of amino acid residues of histone tails driven by histone acetylases (HATs) and histone deacetylases (HDACs) have been shown to affect inflammatory responses, which drive the development of NAFLD [84]. For example, increased activity of HAT has been described to increase transcription of hepatocyte carbohydrate-responsive element-binding protein (chEBP), a well-described activator of genes involved in acute phase response and lipogenesis [109]. Sirtuins (SIRT), a type of HDAC, attenuates responses to metabolic stress [110]. SIRT1 is demonstrated to have a protective effect on NAFLD

and other metabolic conditions and its deletion was associated with increasing severity of hepatic steatosis [110,111]. Lately, a murine knock-out model has shown that a lack of SIRT2 is associated with increased lipogenesis and fibrosis, suggesting a crucial role for histone modification in the NAFLD progression to fibrosis [112].

miRNAs are non-coding RNAs that target messenger RNAs for degradation and regulate their expression [94]. Modifications in the hepatic miRNA profile have been associated with NASH and HCC [113]. Mi-122, the most common miRNA in the liver, has been associated with tumorigenesis due to the deletion of its tumor suppressor effects [113]. It is also associated with NASH and liver fibrosis by activating tissue remodeling genes [94]. Upregulation of mi-192 is also associated with an increased incidence of NASH and has been proposed to be part of the miRNA panel to identify NASH [114]. In addition, mi-166 has shown an association with fibrosis in the Chinese population [115]. Other miRNAs such as mi-21, mi-34a, and mi-16 have also been associated with NASH [94]. Recently, miR-374a, miR-143, miR-1, miR-23a, and miR-423 have also been associated with NASH and target mitochondrial genes and genes involved in lipogenesis, apoptosis, and fibrogenesis [116]. Further research is necessary to validate these miRNAs to develop non-invasive biomarkers.

Mitochondrial senescence

Whatever the primary etiology of NASH, mitochondrial senescence (especially respiratory chain insufficiency) plays a major role in the physiopathology of the disease. Senescence is a form of cellular adaptation to various normal and abnormal cellular processes. It follows different forms of stresses such as changes in the structure of chromatin, stress involving oxidation, and activation of oncogenes [117]. Senescence in hepatocytes and other supporting cells of the liver such as sinusoidal endothelial cells, hepatic stellate cells, and Kupffer cells are closely related to the development and progression of NAFLD [118].

Mitochondrial changes in senescent cells include increased size and amount of tricarboxylic acid byproducts, an increase in the number of mitochondria, ROS, and proton leaks, and a decrease in the function and the membrane potential [119,120]. In 2001, a study conducted by Sanyal et al. found many morphological differences in the mitochondria of a normal liver and that of a NASH patient. NASH was linked with swollen and round mitochondria, clear matrix, loss of mitochondrial cristae, and multiple paracrystalline inclusions, although no indication of a widespread deficiency in fatty acid beta-oxidation was found in any of the groups [121]. Intramitochondrial paracrystalline bodies were associated with NASH with very strong specificity compared with normal controls, fatty liver, and hepatitis C patients.

Though the beta-oxidation of fatty acids was not much affected in the hepatocytes, the defective respiratory chain in the hepatocyte mitochondria generated increased ROS. In a lipid-rich microenvironment, ROS production increases lipid peroxidation, which is toxic to the hepatocytes. ROS harms the respiratory chain due to oxidative damage to the mitochondrial DNA, which starts a vicious cycle [122]. The involvement of mitochondrial senescence in the pathophysiology of NAFLD was reinforced when studies concluded the association between drugs causing steatohepatitis and mitochondrial dysfunction. Drugs like amiodarone or perhexiline cause impairment of electron transfer in the respiratory chain and inhibit beta-oxidation leading to dysfunctional hepatocyte and death [123].

When senescence occurs, its degree is directly proportional to the extent of NAFLD. Some markers support senescence in the liver with NAFLD, and this includes p53, p21, p16, and, more specifically, senescence marker protein-30 (SMP30) [124-126]. SMP30 is involved in ROS and glucose breakdown and maintains calcium balance, but levels of SMP30 reduce with age [127]. Studies have shown that SMP30 reduces further in NAFLD [127]. A decrease in the amount of SMP30 causes fat accumulation in the liver and eventual death of hepatocytes due to the disruption of its metabolism [128].

¹³C-ketoisocaproic acid (KICA) and methionine are markers of mitochondrial function. Breath tests using them as biomarkers showed a significant reduction in carboxylation in patients of NASH but not in patients with fatty liver [129]. Due to high localization in the mitochondria, the urea cycle metabolites have also been used as a non-invasive biomarker for staging and prognosis of NAFLD [130]. These novel methods should be used in the early detection and limitation of progression of NAFLD. However, it remains unclear whether the link between mitochondrial defects and NASH is the cause or an effect of the disease.

Complications and prognosis of NAFLD

Hepatic Complications

As previously mentioned, NAFLD is a spectrum of diseases mainly composed of patients with simple steatosis. In some patients, it can progress to a more advanced disease characterized by NASH and liver fibrosis and cirrhosis, or even HCC [131]. In a retrospective analysis of 619 patients with NAFLD, Angulo et al. concluded that the severity of liver fibrosis is associated with increased long-term mortality and other liver-related complications [132]. However, a collaborative cohorts study by Bhala et al. showed that patients with NAFLD (biopsy-confirmed) with advanced fibrosis had lower rates of hepatic complications and HCC in

comparison with patients with hepatitis C virus (HCV) infection, but overall mortality was the same in both groups [133].

The prevalence of HCC among NAFLD patients is increasing, particularly in developed countries, as suggested by Kim and El-Serag [134]. Currently, limited studies have suggested exact mechanisms of HCC in NAFLD patients. On the other hand, in a cohort study consisting of 130 NAFLD patients, Kanwal et al. concluded that there was an increased risk of HCC and cirrhosis with stepwise addition of each metabolic trait. Their results showed that type 2 diabetes mellitus (T2DM) conferred the highest risk of progression to HCC and suggested T2DM is an essential target for secondary prevention [135].

As with the increasing incidence of NASH, the incidence of NASH-related liver transplantation is increasing. A retrospective cohort study was done by Cholanckeril et al. concluding that NASH is the most rapidly growing indication and currently the second leading indication for liver transplant [136].

Extrahepatic Complications

NAFLD is a multisystem disease and is closely associated with many extra-hepatic complications such as CVD, CKD, and certain malignancies. Among all, CVD is the most common cause of death in patients with NAFLD [137,138]. A meta-analysis including 16 observational prospective and retrospective studies by Targher et al. showed that patients with NAFLD had a higher incidence of CVD events than patients without NAFLD [139]. In another meta-analysis involving 27 cross-section studies, Oni et al. concluded that there is a strong association of NAFLD with several CVD complications such as increased carotid wall thickness, impaired flow-mediated vasodilation, increased arterial stiffness, and subclinical atherosclerosis, which is independent of traditional CVD risk factors and metabolic syndromes [140].

The link between NAFLD and the development of T2DM has been well established by several studies in the past decade; however, the mechanism linking both conditions is multifactorial [141].

As previously mentioned, CKD is a well-established complication of NAFLD. Patients with NAFLD/NASH have a higher prevalence of CKD than patients without NAFLD/NASH. Although the exact pathogenic mechanism linking NAFLD and CKD is not well understood, it is believed that proinflammatory mediators released as a result of liver inflammation in patients with NAFLD cause an increase in pro-oxidative and pro-fibrotic molecules, which play a key role in the mechanism of CKD [142].

Several studies conducted in recent years have established an important link between NAFLD and colorectal carcinoma (CRC) and suggested NAFLD as an independent risk factor for the development of colon polyps and eventually colorectal adenocarcinoma. Inflammation of the liver due to NAFLD causes increased levels of proinflammatory and procoagulant factors and decreases levels of adipokines and adiponectin (protective factors), thus contributing to the pathogenesis of CRC in patients with NAFLD [143]. A correlation between NAFLD and psoriasis with similar pathogenesis (increased proinflammatory cytokines and reduced anti-inflammatory cytokines) has also been demonstrated [144].

A cross-sectional study by Gutierrez-Grobe et al. at the university hospital in Mexico City involving 197 women showed a significant association between NAFLD and polycystic ovarian syndrome (PCOS) and concluded that the prevalence of NAFLD was higher in postmenopausal women and women with PCOS than premenopausal women [145]. In the past few years, several experiments have suggested a possible connection between chronic intermittent hypoxia of obstructive sleep apnea syndrome (OSAS) and NAFLD. A meta-analysis done by Musso et al., including 18 cross-sectional studies, established a link between OSAS and a higher risk of NAFLD [146].

Treatment of NAFLD

Weight loss through lifestyle modifications such as hypocaloric diets and physical exercise remains the primary and most effective treatment for NAFLD of all stages [147]. The American Association for the Study of Liver Disease (AASLD) recommends a minimum of 3-5% loss of body weight to improve hepatic steatosis and a more significant percent weight loss (7-10%) to improve features of NASH [17]. Although there is a lack of global consensus on a specific dietary strategy, the Mediterranean diet, rich in omega-3-unsaturated polyunsaturated fatty acids, is recommended by multiple European organizations as the best solution [148].

Pharmacological intervention is indicated only in the case of NASH [17]. The use of several pharmacologic agents has been explored; however, the supporting data are limited and largely empirical with many of their clinical trials occurring in uncontrolled environments. Currently, pioglitazone, a thiazolidinedione, is the only insulin-sensitizing agent recommended by AASLD to patients with NASH [17]. Vitamin E, with its antioxidant anti-inflammatory and anti-apoptotic properties, is recommended by AASLD only in nondiabetic patients with biopsy-proven NASH [17]. Monitoring of older male patients is indicated during continuous use for more than three years, due to an increased risk of prostate cancer [149-151]. Lipid-lowering agents (statins, fibrates, and ezetimibe) can reduce FFAs and triglyceride deposition in hepatocytes, decreasing disease progression [152]. This exploits the positive correlation between subclinical

atherosclerosis and progression and mortality in NASH patients [152]. Surgical management of NASH is performed in cases of complications such as cirrhosis or HCC [153]. NASH-related cirrhosis and HCC are increasingly common indications for liver transplantation in the West [154]. Bariatric surgery has been shown to reverse histological features of NASH; however, it is not recognized as a treatment for NASH and is only indicated in severe obesity to aid weight loss [17,155].

The use of obeticholic acid has been found to noticeably improve the histological changes in patients with early stages of fibrosis in NASH, but the outcome is unsatisfactory in advanced NAFLD. In individuals with T2DM and NAFLD, the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, like empagliflozin and dapagliflozin, lowers liver fat and raises ALT levels [153,154]. Newer thiazolidinediones like saroglitazar (a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist, approved for diabetic dyslipidemia) and elafibranor (an agonist of PPAR- α and PPAR- δ) have shown improvement in insulin resistance and serum lipid normalization, which are two important causes of NASH progression. The safety profile is excellent, although it causes reversible serum creatinine increases, which may limit its use in individuals with a renal illness. It calls for the personalization of drug combinations, depending on the stage of NASH and associated morbidities for each patient [154].

Established medications are being explored as potential therapies for NAFLD. For example, liraglutide, a glucagon-like peptide 1, has been demonstrated to cause a resolution in the histological features of NASH and can be considered as a potential treatment [156]. Other naturally occurring substances such as silymarin, betaine, quercetin, and probiotics have shown mixed results and may be used along with other therapies [157]. Several new medications targeting pathways driving progression are also in development. Cenicriviroc, a chemokine antagonist targeting pro-inflammatory pathways, was investigated for NASH treatment [158]. Selonsertib, which modulates cell death via apoptosis signal-regulating kinase-1, was considered [159]. Drugs targeting fibrogenesis such as simtuzumab were also researched [160]. However, their viability as treatments remains limited, possibly due to the complexity of the targeted pathways. Development of new pharmacological agents and their validation through large-scale randomized controlled trials are required to offset the increase in NASH-indicated liver transplantations.

Conclusions

NAFLD is a very broad disease, with multiple risk factors acting in concert to manifest its numerous clinical consequences. The incidence of risk factors associated with this disease, such as diabetes mellitus, for instance, is increasing rapidly across the world, increasing the prevalence of NAFLD. Despite repeated efforts by multiple teams from across the world, there is still no cure for NAFLD. Therefore, its management is focused on the prevention and early detection of this disease.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Chalasani N, Younossi Z, Lavine JE, et al.: The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology*. 2012, 55:2005-23. [10.1002/hep.25762](https://doi.org/10.1002/hep.25762)
2. Tiniakos DG, Vos MB, Brunt EM: Nonalcoholic fatty liver disease: pathology and pathogenesis. *Annu Rev Pathol*. 2010, 5:145-71. [10.1146/annurev-pathol-121808-102132](https://doi.org/10.1146/annurev-pathol-121808-102132)
3. Ludwig J, Viggiano TR, McGill DB, Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc*. 1980, 55:434-8.
4. Lindemeyer CC, McCullough AJ: The natural history of nonalcoholic fatty liver disease—an evolving view. *Clin Liver Dis*. 2018, 22:11-21. [10.1016/j.cld.2017.08.003](https://doi.org/10.1016/j.cld.2017.08.003)
5. Fang YL, Chen H, Wang CL, Liang L: Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from "two hit theory" to "multiple hit model". *World J Gastroenterol*. 2018, 24:2974-83. [10.3748/wjg.v24.i27.2974](https://doi.org/10.3748/wjg.v24.i27.2974)
6. Alisi A, Cianfarani S, Manco M, Agostoni C, Nobili V: Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. *Ann Med*. 2012, 44:29-40. [10.3109/07853890.2010.547869](https://doi.org/10.3109/07853890.2010.547869)
7. Vajro P, Lenta S, Socha P, et al.: Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. *J Pediatr Gastroenterol Nutr*. 2012, 54:700-13. [10.1097/MPG.0b013e318252a13f](https://doi.org/10.1097/MPG.0b013e318252a13f)
8. Chen ZW, Chen LY, Dai HL, Chen JH, Fang LZ: Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. *J Zhejiang Univ Sci B*. 2008, 9:616-22.

- 10.1631/jzus.B0720016
9. Clark JM: The epidemiology of nonalcoholic fatty liver disease in adults . *J Clin Gastroenterol*. 2006, 40:S5-10. [10.1097/01.mcj.0000168638.84840.ff](#)
10. Michelotti GA, Machado MV, Diehl AM: NAFLD, NASH and liver cancer. *Nat Rev Gastroenterol Hepatol*. 2013, 10:656-65. [10.1038/nrgastro.2013.183](#)
11. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M: Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016, 64:73-84. [10.1002/hep.28431](#)
12. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A: Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. *Gastroenterology*. 2015, 148:547-55. [10.1053/j.gastro.2014.11.039](#)
13. Zelber-Sagi S, Ratzliff V, Oren R: Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. *World J Gastroenterol*. 2011, 17:3377-89. [10.3748/wjg.v17.i29.3377](#)
14. Day CP: Non-alcoholic fatty liver disease: a massive problem . *Clin Med (Lond)*. 2011, 11:176-8. [10.7861/clinmedicine.11-2-176](#)
15. Alisi A, Nobili V: Nonalcoholic fatty liver disease: targeted therapy in children--what is the right way? . *Nat Rev Gastroenterol Hepatol*. 2011, 8:425-6. [10.1038/nrgastro.2011.117](#)
16. Bessone F, Razori MV, Roma MG: Molecular pathways of nonalcoholic fatty liver disease development and progression. *Cell Mol Life Sci*. 2019, 76:99-128. [10.1007/s00018-018-2947-0](#)
17. Chalasani N, Younossi Z, Lavine JE, et al.: The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*. 2018, 67:328-57. [10.1002/hep.29367](#)
18. Italian Association for the Study of the Liver (AISF): AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. *Dig Liver Dis*. 2017, 49:471-83. [10.1016/j.dld.2017.01.147](#)
19. Buzzetti E, Pinzani M, Tsochatzis EA: The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). *Metabolism*. 2016, 65:1038-48. [10.1016/j.metabol.2015.12.012](#)
20. Peverill W, Powell LW, Skoien R: Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. *Int J Mol Sci*. 2014, 15:8591-638. [10.3390/ijms15058591](#)
21. García-Monzón C, Lo Iacono O, Mayoral R, et al.: Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. *J Hepatol*. 2011, 54:142-52. [10.1016/j.jhep.2010.06.021](#)
22. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ: Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. *Gastroenterology*. 2003, 125:437-43. [10.1016/s0016-5085\(03\)00907-7](#)
23. Pardo V, González-Rodríguez Á, Muntané J, Kozma SC, Valverde ÁM: Role of hepatocyte S6K1 in palmitic acid-induced endoplasmic reticulum stress, lipotoxicity, insulin resistance and in oleic acid-induced protection. *Food Chem Toxicol*. 2015, 80:298-309. [10.1016/j.fct.2015.03.029](#)
24. Gastaldelli A, Cusi K: From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. *JHEP Rep*. 2019, 1:312-28. [10.1016/j.jhepr.2019.07.002](#)
25. Gancheva S, Jelenik T, Álvarez-Hernández E, Roden M: Interorgan metabolic crosstalk in human insulin resistance. *Physiol Rev*. 2018, 98:1371-415. [10.1152/physrev.00015.2017](#)
26. Jacome-Sosa MM, Parks EJ: Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans. *Curr Opin Lipidol*. 2014, 25:213-20. [10.1097/MOL.0000000000000080](#)
27. Tilg H, Moschen AR, Roden M: NAFLD and diabetes mellitus. *Nat Rev Gastroenterol Hepatol*. 2017, 14:32-42. [10.1038/nrgastro.2016.147](#)
28. Samuel VT, Shulman GI: Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases . *Cell Metab*. 2018, 27:22-41. [10.1016/j.cmet.2017.08.002](#)
29. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ: Mechanisms of NAFLD development and therapeutic strategies. *Nat Med*. 2018, 24:908-22. [10.1038/s41591-018-0104-9](#)
30. Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM: Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. *Hepatology*. 2012, 56:943-51. [10.1002/hep.25772](#)
31. Sabio G, Das M, Mora A, et al.: A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. *Science*. 2008, 322:1539-43. [10.1126/science.1160794](#)
32. Tilg H: The role of cytokines in non-alcoholic fatty liver disease . *Dig Dis*. 2010, 28:179-85. [10.1159/000282083](#)
33. Ghorpade DS, Ozcan L, Zheng Z, et al.: Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. *Nature*. 2018, 555:673-7. [10.1038/nature26138](#)
34. Ozcan U, Cao Q, Yilmaz E, et al.: Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. *Science*. 2004, 306:457-61. [10.1126/science.1103160](#)
35. Chen Z, Tian R, She Z, Cai J, Li H: Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. *Free Radic Biol Med*. 2020, 152:116-41. [10.1016/j.freeradbiomed.2020.02.025](#)
36. Sies H: Oxidative stress: from basic research to clinical application . *Am J Med*. 1991, 91:S31-8. [10.1016/0002-9343\(91\)90281-2](#)
37. Sunny NE, Bril F, Cusi K: Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies. *Trends Endocrinol Metab*. 2017, 28:250-60. [10.1016/j.tem.2016.11.006](#)
38. Ore A, Akinloye OA: Oxidative stress and antioxidant biomarkers in clinical and experimental models of non-alcoholic fatty liver disease. *Medicina (Kaunas)*. 2019, 55:26. [10.3390/medicina55020026](#)
39. Kushnareva Y, Murphy AN, Andreyev A: Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)⁺ oxidation-reduction state. *Biochem J*. 2002, 368:545-53. [10.1042/BJ20021121](#)
40. Spahis S, Delvin E, Borys JM, Levy E: Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis. *Antioxid Redox Signal*. 2017, 26:519-41. [10.1089/ars.2016.6776](#)

41. Lee J, Park JS, Roh YS: Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease . *Arch Pharm Res*. 2019, 42:935-46. [10.1007/s12272-019-01178-1](#)
42. Tacke F: Targeting hepatic macrophages to treat liver diseases . *J Hepatol*. 2017, 66:1300-12. [10.1016/j.jhep.2017.02.026](#)
43. Csak T, Pillai A, Ganz M, et al.: Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis. *Liver Int*. 2014, 34:1402-13. [10.1111/liv.12537](#)
44. Grunhut J, Wang W, Aykut B, Gakhal I, Torres-Hernandez A, Miller G: Macrophages in nonalcoholic steatohepatitis: friend or foe?. *Eur Med J Hepatol*. 2018, 6:100-109.
45. Zazos P, Renner EL: Liver transplantation and non-alcoholic fatty liver disease . *World J Gastroenterol*. 2014, 20:15532-8. [10.3748/wjg.v20.i42.15532](#)
46. Bzowej NH: Nonalcoholic steatohepatitis: the new frontier for liver transplantation . *Curr Opin Organ Transplant*. 2018, 23:169-74. [10.1097/MOT.0000000000000502](#)
47. Starley BQ, Calcagno CJ, Harrison SA: Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. *Hepatology*. 2010, 51:1820-32. [10.1002/hep.23594](#)
48. Zheng Y, Ley SH, Hu FB: Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol*. 2018, 14:88-98. [10.1038/nrendo.2017.151](#)
49. Rinella ME: Nonalcoholic fatty liver disease: a systematic review . *JAMA*. 2015, 313:2263-73. [10.1001/jama.2015.5370](#)
50. Musso G, Gambino R, Tabibian JH, et al.: Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. *PLoS Med*. 2014, 11:e1001680. [10.1371/journal.pmed.1001680](#)
51. Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A: COVID-19 and non-alcoholic fatty liver disease: two intersecting pandemics. *Eur J Clin Invest*. 2020, 50:e13338. [10.1111/eci.13338](#)
52. Pan JJ, Fallon MB: Gender and racial differences in nonalcoholic fatty liver disease . *World J Hepatol*. 2014, 6:274-83. [10.4254/wjh.v6.i5.274](#)
53. Brumbaugh DE, Friedman JE: Developmental origins of nonalcoholic fatty liver disease . *Pediatr Res*. 2014, 75:140-7. [10.1038/pr.2013.193](#)
54. Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM: Epidemiology and natural history of non-alcoholic fatty liver disease. *Metabolism*. 2016, 65:1017-25. [10.1016/j.metabol.2016.01.012](#)
55. Lazo M, Hernaez R, Eberhardt MS, et al.: Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. *Am J Epidemiol*. 2013, 178:38-45. [10.1093/aje/kws448](#)
56. Mitra S, De A, Chowdhury A: Epidemiology of non-alcoholic and alcoholic fatty liver diseases . *Transl Gastroenterol Hepatol*. 2020, 5:16. [10.21037/tgh.2019.09.08](#)
57. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F: The burden of liver disease in Europe: a review of available epidemiological data. *J Hepatol*. 2013, 58:593-608. [10.1016/j.jhep.2012.12.005](#)
58. Farrell GC, Wong VW, Chitturi S: NAFLD in Asia--as common and important as in the West . *Nat Rev Gastroenterol Hepatol*. 2013, 10:307-18. [10.1038/nrgastro.2013.34](#)
59. Paruk IM, Pirie FJ, Motala AA: Non-alcoholic fatty liver disease in Africa: a hidden danger . *Glob Health Epidemiol Genom*. 2019, 4:e3. [10.1017/ghg.2019.2](#)
60. Lazo M, Clark JM: The epidemiology of nonalcoholic fatty liver disease: a global perspective . *Semin Liver Dis*. 2008, 28:339-50. [10.1055/s-0028-1091978](#)
61. Samji NS, Snell PD, Singal AK, Satapathy SK: Racial disparities in diagnosis and prognosis of nonalcoholic fatty liver disease. *Clin Liver Dis (Hoboken)*. 2020, 16:66-72. [10.1002/cld.948](#)
62. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR: Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. *Liver Int*. 2009, 29:113-9. [10.1111/j.1478-3231.2008.01718.x](#)
63. Al-Goblan AS, Al-Alfi MA, Khan MZ: Mechanism linking diabetes mellitus and obesity. *Diabetes Metab Syndr Obes*. 2014, 7:587-91. [10.2147/DMSO.S67400](#)
64. Masuoka HC, Chalasani N: Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. *Ann N Y Acad Sci*. 2013, 1281:106-22. [10.1111/nyas.12016](#)
65. Motamed N, Sohrabi M, Ajdarkosh H, et al.: Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease. *World J Gastroenterol*. 2016, 22:3023-30. [10.3748/wjg.v22.i10.3023](#)
66. Loomis AK, Kabadi S, Preiss D, et al.: Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies. *J Clin Endocrinol Metab*. 2016, 101:945-52. [10.1210/jc.2015-3444](#)
67. Nseir W, Hellou E, Assy N: Role of diet and lifestyle changes in nonalcoholic fatty liver disease . *World J Gastroenterol*. 2014, 20:9338-44. [10.3748/wjg.v20.i28.9338](#)
68. Asgari-Taee F, Zerafati-Shoae N, Dehghani M, Sadeghi M, Baradaran HR, Jazayeri S: Association of sugar sweetened beverages consumption with non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Eur J Nutr*. 2019, 58:1759-69. [10.1007/s00394-018-1711-4](#)
69. Alferink LJM, Trajanoska K, Erler NS, et al.: Nonalcoholic fatty liver disease in the Rotterdam Study: about muscle mass, sarcopenia, fat mass, and fat distribution. *J Bone Miner Res*. 2019, 34:1254-63. [10.1002/jbmr.3713](#)
70. Koo BK, Kim D, Joo SK, et al.: Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. *J Hepatol*. 2017, 66:123-31. [10.1016/j.jhep.2016.08.019](#)
71. DiStefano JK: NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment . *Endocrinology*. 2020, 161:bqaa134. [10.1210/endo/bqaa134](#)
72. Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A: NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. *Adv Ther*. 2017, 34:1291-326. [10.1007/s12325-017-0556-1](#)
73. Hossain N, Afendy A, Stepanova M, et al.: Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol*. 2009, 7:1224-9. [10.1016/j.cgh.2009.06.007](#)

74. Tasneem AA, Luck NH, Majid Z: Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). *Trop Doct.* 2018, 48:107-12. [10.1177/0049475517742261](https://doi.org/10.1177/0049475517742261)
75. Simon J, Ouro A, Ala-Ibanibo L, Presa N, Delgado TC, Martínez-Chantar ML: Sphingolipids in non-alcoholic fatty liver disease and hepatocellular carcinoma: ceramide turnover. *Int J Mol Sci.* 2019, 21:40. [10.3390/ijms21010040](https://doi.org/10.3390/ijms21010040)
76. Montefusco DJ, Allegood JC, Spiegel S, Cowart LA: Non-alcoholic fatty liver disease: insights from sphingolipidomics. *Biochem Biophys Res Commun.* 2018, 504:608-16. [10.1016/j.bbrc.2018.05.078](https://doi.org/10.1016/j.bbrc.2018.05.078)
77. Seko Y, Sumida Y, Tanaka S, et al.: Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. *Hepatol Res.* 2015, 45:E53-61. [10.1111/hepr.12456](https://doi.org/10.1111/hepr.12456)
78. Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX: Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments. *Front Pharmacol.* 2020, 11:603926. [10.3389/fphar.2020.603926](https://doi.org/10.3389/fphar.2020.603926)
79. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM: Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. *J Hepatol.* 2015, 62:1148-55. [10.1016/j.jhep.2014.11.034](https://doi.org/10.1016/j.jhep.2014.11.034)
80. Vernon G, Baranova A, Younossi ZM: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther.* 2011, 34:274-85. [10.1111/j.1365-2036.2011.04724.x](https://doi.org/10.1111/j.1365-2036.2011.04724.x)
81. Dam-Larsen S, Franzmann M, Andersen IB, et al.: Long term prognosis of fatty liver: risk of chronic liver disease and death. *Gut.* 2004, 53:750-5. [10.1136/gut.2003.019984](https://doi.org/10.1136/gut.2003.019984)
82. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R: Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. *Clin Gastroenterol Hepatol.* 2015, 13:643-54. [10.1016/j.cgh.2014.04.014](https://doi.org/10.1016/j.cgh.2014.04.014)
83. Sookoian S, Pirola CJ: Genetic predisposition in nonalcoholic fatty liver disease. *Clin Mol Hepatol.* 2017, 23:1-12. [10.3350/cmh.2016.0109](https://doi.org/10.3350/cmh.2016.0109)
84. Romeo S, Kozlitina J, Xing C, et al.: Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet.* 2008, 40:1461-5. [10.1038/ng.257](https://doi.org/10.1038/ng.257)
85. Sookoian S, Pirola CJ: Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. *Hepatology.* 2011, 53:1883-94. [10.1002/hep.24283](https://doi.org/10.1002/hep.24283)
86. He S, McPhaul C, Li JZ, et al.: A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. *J Biol Chem.* 2010, 285:6706-15. [10.1074/jbc.M109.064501](https://doi.org/10.1074/jbc.M109.064501)
87. Liu YL, Patman GL, Leathart JB, et al.: Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. *J Hepatol.* 2014, 61:75-81. [10.1016/j.jhep.2014.02.030](https://doi.org/10.1016/j.jhep.2014.02.030)
88. Luukkonen PK, Zhou Y, Hyötyläinen T, et al.: The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. *J Hepatol.* 2016, 65:1263-5. [10.1016/j.jhep.2016.07.045](https://doi.org/10.1016/j.jhep.2016.07.045)
89. Mancina RM, Dongiovanni P, Petta S, et al.: The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. *Gastroenterology.* 2016, 150:1219-30.e6. [10.1053/j.gastro.2016.01.032](https://doi.org/10.1053/j.gastro.2016.01.032)
90. Teo K, Abeysekera KW, Adams L, et al.: rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis. *J Hepatol.* 2021, 74:20-30. [10.1016/j.jhep.2020.08.027](https://doi.org/10.1016/j.jhep.2020.08.027)
91. Donati B, Dongiovanni P, Romeo S, et al.: MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. *Sci Rep.* 2017, 7:4492. [10.1038/s41598-017-04991-0](https://doi.org/10.1038/s41598-017-04991-0)
92. Kozlitina J, Smagris E, Stender S, et al.: Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet.* 2014, 46:352-6. [10.1038/ng.2901](https://doi.org/10.1038/ng.2901)
93. Liu YL, Reeves HL, Burt AD, et al.: TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. *Nat Commun.* 2014, 5:4309. [10.1038/ncomms5309](https://doi.org/10.1038/ncomms5309)
94. Eslam M, Valenti L, Romeo S: Genetics and epigenetics of NAFLD and NASH: clinical impact. *J Hepatol.* 2018, 68:268-79. [10.1016/j.jhep.2017.09.003](https://doi.org/10.1016/j.jhep.2017.09.003)
95. Lisboa QC, Nardelli MJ, Pereira PA, et al.: PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. *World J Hepatol.* 2020, 12:792-806. [10.4254/wjh.v12.i10.792](https://doi.org/10.4254/wjh.v12.i10.792)
96. Speliotes EK, Yerges-Armstrong LM, Wu J, et al.: Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. *PLoS Genet.* 2011, 7:e1001324. [10.1371/journal.pgen.1001324](https://doi.org/10.1371/journal.pgen.1001324)
97. Abul-Husn NS, Cheng X, Li AH, et al.: A protein-truncating HSD17B13 variant and protection from chronic liver disease. *N Engl J Med.* 2018, 378:1096-106. [10.1056/NEJMoa1712191](https://doi.org/10.1056/NEJMoa1712191)
98. Petta S, Grimaudo S, Cammà C, et al.: IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. *J Hepatol.* 2012, 56:1356-62. [10.1016/j.jhep.2012.01.007](https://doi.org/10.1016/j.jhep.2012.01.007)
99. Al-Serri A, Anstee QM, Valenti L, et al.: The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. *J Hepatol.* 2012, 56:448-54. [10.1016/j.jhep.2011.05.029](https://doi.org/10.1016/j.jhep.2011.05.029)
100. Vespasiani-Gentilucci U, Gallo P, Dell'Unto C, Volpentesta M, Antonelli-Incalzi R, Picardi A: Promoting genetics in non-alcoholic fatty liver disease: combined risk score through polymorphisms and clinical variables. *World J Gastroenterol.* 2018, 24:4835-45. [10.3748/wjg.v24.i43.4835](https://doi.org/10.3748/wjg.v24.i43.4835)
101. Bianco C, Jamialahmadi O, Pelusi S, et al.: Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. *J Hepatol.* 2021, 74:775-82. [10.1016/j.jhep.2020.11.024](https://doi.org/10.1016/j.jhep.2020.11.024)
102. Larrieta-Carrasco E, Flores YN, Macías-Kauffer LR, et al.: Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population. *Exp Mol Pathol.* 2018, 104:50-8. [10.1016/j.yexmp.2018.01.001](https://doi.org/10.1016/j.yexmp.2018.01.001)
103. Jamialahmadi O, Mancina RM, Ciociola E, et al.: Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease. *Gastroenterology.* 2021, 160:1634-46.e7. [10.1053/j.gastro.2020.12.023](https://doi.org/10.1053/j.gastro.2020.12.023)

104. Lee J, Kim Y, Friso S, Choi SW: Epigenetics in non-alcoholic fatty liver disease . *Mol Aspects Med.* 2017, 54:78-88. [10.1016/j.mam.2016.11.008](#)
105. Kitamoto T, Kitamoto A, Ogawa Y, et al.: Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. *J Hepatol.* 2015, 63:494-502. [10.1016/j.jhep.2015.02.049](#)
106. Johnson ND, Wu X, Still CD, et al.: Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD. *Clin Epigenetics.* 2021, 13:152. [10.1186/s13148-021-01129-y](#)
107. Pirola CJ, Gianotti TF, Burgueño AL, et al.: Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. *Gut.* 2013, 62:1356-63. [10.1136/gutjnl-2012-302962](#)
108. Hajri T, Zaiou M, Fungwe TV, Ouguerram K, Besong S: Epigenetic regulation of peroxisome proliferator-activated receptor gamma mediates high-fat diet-induced non-alcoholic fatty liver disease. *Cells.* 2021, 10:1355. [10.3390/cells10061355](#)
109. Kim H, Mendez R, Chen X, Fang D, Zhang K: Lysine acetylation of CREBH regulates fasting-induced hepatic lipid metabolism. *Mol Cell Biol.* 2015, 35:4121-34. [10.1128/MCB.00665-15](#)
110. Kobayashi Y, Furukawa-Hibi Y, Chen C, Horio Y, Isobe K, Ikeda K, Motoyama N: SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. *Int J Mol Med.* 2005, 16:237-43.
111. Mariani S, Fiore D, Basciani S, et al.: Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients. *Endocrine.* 2015, 49:711-6. [10.1007/s12020-014-0465-x](#)
112. Park S, Chung MJ, Son JY, et al.: The role of sirtuin 2 in sustaining functional integrity of the liver . *Life Sci.* 2021, 285:119997. [10.1016/j.lfs.2021.119997](#)
113. Cheung O, Puri P, Eicken C, et al.: Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. *Hepatology.* 2008, 48:1810-20. [10.1002/hep.22569](#)
114. Liu XL, Pan Q, Zhang RN, et al.: Disease-specific miR-54a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. *World J Gastroenterol.* 2016, 22:9844-52. [10.3748/wjg.v22.i44.9844](#)
115. Tan Y, Ge G, Pan T, Wen D, Gan J: A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. *PLoS One.* 2014, 9:e105192. [10.1371/journal.pone.0105192](#)
116. Vulf M, Shunkina D, Komar A, et al.: Analysis of miRNAs profiles in serum of patients with steatosis and steatohepatitis. *Front Cell Dev Biol.* 2021, 9:736677. [10.3389/fcell.2021.736677](#)
117. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS: The essence of senescence . *Genes Dev.* 2010, 24:2463-79. [10.1101/gad.1971610](#)
118. Meijnikman AS, Herrema H, Scheithauer TP, Kroon J, Nieuwdorp M, Groen AK: Evaluating causality of cellular senescence in non-alcoholic fatty liver disease. *JHEP Rep.* 2021, 3:100301. [10.1016/j.jhepr.2021.100301](#)
119. Passos JF, Nelson G, Wang C, et al.: Feedback between p21 and reactive oxygen production is necessary for cell senescence. *Mol Syst Biol.* 2010, 6:347. [10.1038/msb.2010.5](#)
120. Passos JF, Saretzki G, Ahmed S, et al.: Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. *PLoS Biol.* 2007, 5:e110. [10.1371/journal.pbio.0050110](#)
121. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al.: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. *Gastroenterology.* 2001, 120:1183-92. [10.1053/gast.2001.23256](#)
122. Begriche K, Igoudjil A, Pessayre D, Fromenty B: Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. *Mitochondrion.* 2006, 6:1-28. [10.1016/j.mito.2005.10.004](#)
123. Berson A, De Beco V, Lettéron P, et al.: Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. *Gastroenterology.* 1998, 114:764-74. [10.1016/s0016-5085\(98\)70590-6](#)
124. Zhang J, Li Y, Wang B, Luo Y, Shi J, Zhao B: The p66shc-mediated regulation of hepatocyte senescence influences hepatic steatosis in nonalcoholic fatty liver disease. *Med Sci Monit.* 2020, 26:e921887. [10.12659/MSM.921887](#)
125. Ogrodnik M, Miwa S, Tchkonja T, et al.: Cellular senescence drives age-dependent hepatic steatosis . *Nat Commun.* 2017, 8:15691. [10.1038/ncomms15691](#)
126. Akazawa Y, Nakashima R, Matsuda K, et al.: Detection of DNA damage response in nonalcoholic fatty liver disease via p53-binding protein 1 nuclear expression. *Mod Pathol.* 2019, 32:997-1007. [10.1038/s41379-019-0218-8](#)
127. Al-Ghamdi HA, Al Fayed FF, Bima AI, Khawaji TM, Elsamanoudy AZ: Study of cellular senescence and vitamin D deficiency in nonalcoholic fatty liver disease and the potential protective effect of vitamin D supplementation. *J Clin Exp Hepatol.* 2021, 11:219-26. [10.1016/j.jceh.2020.07.003](#)
128. Kondo Y, Masutomi H, Noda Y, et al.: Senescence marker protein-30/superoxide dismutase 1 double knockout mice exhibit increased oxidative stress and hepatic steatosis. *FEBS Open Bio.* 2014, 4:522-32. [10.1016/j.fob.2014.05.003](#)
129. Di Ciaula A, Calamita G, Shanmugam H, et al.: Mitochondria matter: systemic aspects of nonalcoholic fatty liver disease (NAFLD) and diagnostic assessment of liver function by stable isotope dynamic breath tests. *Int J Mol Sci.* 2021, 22:7702. [10.3390/ijms22147702](#)
130. Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Nedosugova LV, Starodubova AV, Orekhov AN: Mitochondrial mutations and genetic factors determining NAFLD risk . *Int J Mol Sci.* 2021, 22:4459. [10.3390/ijms22094459](#)
131. Ratzliff V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G: A position statement on NAFLD/NASH based on the EASL 2009 special conference. *J Hepatol.* 2010, 53:372-84. [10.1016/j.jhep.2010.04.008](#)
132. Angulo P, Kleiner DE, Dam-Larsen S, et al.: Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology.* 2015, 149:389-97.e10. [10.1053/j.gastro.2015.04.043](#)
133. Bhala N, Angulo P, van der Poorten D, et al.: The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. *Hepatology.* 2011, 54:1208-16. [10.1002/hep.24491](#)
134. Kim HS, El-Serag HB: The epidemiology of hepatocellular carcinoma in the USA . *Curr Gastroenterol Rep.* 2019, 21:17. [10.1007/s11894-019-0681-x](#)

135. Kanwal F, Kramer JR, Li L, et al.: Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. *Hepatology*. 2020, 71:808-19. [10.1002/hep.31014](#)
136. Cholanteril G, Wong RJ, Hu M, et al.: Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. *Dig Dis Sci*. 2017, 62:2915-22. [10.1007/s10620-017-4684-x](#)
137. Younossi ZM: Non-alcoholic fatty liver disease - a global public health perspective. *J Hepatol*. 2019, 70:531-44. [10.1016/j.jhep.2018.10.033](#)
138. Adams LA, Anstee QM, Tilg H, Targher G: Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. *Gut*. 2017, 66:1138-53. [10.1136/gutjnl-2017-313884](#)
139. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C: Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. *J Hepatol*. 2016, 65:589-600. [10.1016/j.jhep.2016.05.013](#)
140. Oni ET, Agatston AS, Blaha MJ, et al.: A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. *Atherosclerosis*. 2013, 230:258-67. [10.1016/j.atherosclerosis.2013.07.052](#)
141. Vanni E, Marengo A, Mezzabotta L, Bugianesi E: Systemic complications of nonalcoholic fatty liver disease: when the liver is not an innocent bystander. *Semin Liver Dis*. 2015, 35:236-49. [10.1055/s-0035-1562944](#)
142. Targher G, Chonchol MB, Byrne CD: CKD and nonalcoholic fatty liver disease. *Am J Kidney Dis*. 2014, 64:638-52. [10.1053/j.ajkd.2014.05.019](#)
143. Mikolasevic I, Milic S, Turk Wensveen T, et al.: Nonalcoholic fatty liver disease - a multisystem disease?. *World J Gastroenterol*. 2016, 22:9488-505. [10.3748/wjg.v22.i43.9488](#)
144. Gisondi P, Galvan A, Idolazzi L, Girolomoni G: Management of moderate to severe psoriasis in patients with metabolic comorbidities. *Front Med (Lausanne)*. 2015, 2:1. [10.3389/fmed.2015.00001](#)
145. Gutierrez-Grobo Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, Méndez-Sánchez N: Prevalence of non alcoholic fatty liver disease in premenopausal, postmenopausal and polycystic ovary syndrome women. The role of estrogens. *Ann Hepatol*. 2010, 9:402-9. [10.1016/S1665-2681\(19\)31616-3](#)
146. Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R: Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. *Obes Rev*. 2013, 14:417-31. [10.1111/obr.12020](#)
147. Del Ben M, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F: Modern approach to the clinical management of non-alcoholic fatty liver disease. *World J Gastroenterol*. 2014, 20:8341-50. [10.3748/wjg.v20.i26.8341](#)
148. Moore MP, Cunningham RP, Dashek RJ, Mucinski JM, Rector RS: A fad too far? Dietary strategies for the prevention and treatment of NAFLD. *Obesity (Silver Spring)*. 2020, 28:1843-52. [10.1002/oby.22964](#)
149. Perumpail BJ, Li AA, John N, et al.: The role of vitamin E in the treatment of NAFLD. *Diseases*. 2018, 6:86. [10.3390/diseases6040086](#)
150. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S: Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. *Am J Gastroenterol*. 2003, 98:2485-90. [10.1111/j.1572-0241.2003.08699.x](#)
151. Klein EA, Thompson IM Jr, Tangen CM, et al.: Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA*. 2011, 306:1549-56. [10.1001/jama.2011.1437](#)
152. Nseir W, Mograbi J, Ghali M: Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. *Dig Dis Sci*. 2012, 57:1773-81. [10.1007/s10620-012-2118-3](#)
153. Asrani SK: Liver transplantation for nonalcoholic steatohepatitis. *Clin Gastroenterol Hepatol*. 2014, 12:403-4. [10.1016/j.cgh.2013.11.014](#)
154. Burra P, Becchetti C, Germani G: NAFLD and liver transplantation: disease burden, current management and future challenges. *JHEP Rep*. 2020, 2:100192. [10.1016/j.jhepr.2020.100192](#)
155. Laursen TL, Hagemann CA, Wei C, Kazankov K, Thomsen KL, Knop FK, Grønbaek H: Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. *World J Hepatol*. 2019, 11:138-49. [10.4254/wjh.v11.i2.138](#)
156. Armstrong MJ, Gaunt P, Aithal GP, et al.: Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet*. 2016, 13:679-90. [10.1016/S0140-6736\(15\)00803-X](#)
157. Mukherjee S: Betaine and nonalcoholic steatohepatitis: back to the future?. *World J Gastroenterol*. 2011, 17:3663-4. [10.3748/wjg.v17.i32.3663](#)
158. Anstee QM, Neuschwander-Tetri BA, Wong VW, et al.: Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA phase 3 study design. *Contemp Clin Trials*. 2020, 89:105922. [10.1016/j.cct.2019.105922](#)
159. Dickson I: No anti-fibrotic effect of selonsertib in NASH. *Nat Rev Gastroenterol Hepatol*. 2020, 17:260. [10.1038/s41575-020-0297-5](#)
160. Harrison SA, Abdelmalek MF, Caldwell S, et al.: Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. *Gastroenterology*. 2018, 155:1140-53. [10.1053/j.gastro.2018.07.006](#)